Metastasis accounts for the most lethal reason for the death of ovarian cancer patients, but remains largely untreated. Epithelial–mesenchymal transition (EMT) is critical for the conversion of ...
The p53–Mdm2 system is key to tumor suppression. We have recently reported that p53 as well as Mdm2 are capable of supporting DNA replication fork progression. On the other hand, we found that Mdm2 is ...
Overexpression of c-met as a Prognostic Indicator for Transitional Cell Carcinoma of the Urinary Bladder: A Comparison With p53 Nuclear Accumulation PURPOSE: Testicular germ cell tumors (TGCTs) of ...
Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral ...
Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective ...
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced ...
The Myc family of transcription factors, including Myc, N-Myc, and L-Myc, bind DNA at specific sequences and regulate gene expression by binding to enhancer-box (E-Box) sequences via dimerization with ...
A study has identified a possible second-line treatment for melanoma patients. A study from Vanderbilt-Ingram Cancer Center and the Department of Veterans Affairs led by Anna Vilgelm, MD, PhD, and Ann ...
This article and associated images are based on a poster originally authored by Sarona Jacob Anderson and presented at ELRIG Drug Discovery 2025 in affiliation with University of Salford. This poster ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 3 (Jan. 18, 2005), pp. 731-736 (6 pages) The MYCN oncogene is the major negative prognostic marker in ...
Roivant Discovery Inc. has disclosed PROTACs (proteolysis targeting chimeras) comprising an E3 ubiquitin ligase binding moiety covalently linked to an E3 ubiquitin-protein ligase Mdm2 (Hdm2)-targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results